Subjects -> MEDICAL SCIENCES (Total: 8821 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (224 journals)
    - ANAESTHESIOLOGY (121 journals)
    - CARDIOVASCULAR DISEASES (350 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (234 journals)
    - DENTISTRY (292 journals)
    - DERMATOLOGY AND VENEREOLOGY (167 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (127 journals)
    - ENDOCRINOLOGY (151 journals)
    - FORENSIC SCIENCES (44 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (192 journals)
    - GERONTOLOGY AND GERIATRICS (143 journals)
    - HEMATOLOGY (159 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (180 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (100 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2458 journals)
    - NURSES AND NURSING (372 journals)
    - OBSTETRICS AND GYNECOLOGY (211 journals)
    - ONCOLOGY (393 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (143 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (172 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (277 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (161 journals)
    - PSYCHIATRY AND NEUROLOGY (848 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (195 journals)
    - RESPIRATORY DISEASES (108 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (83 journals)
    - SURGERY (412 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (159 journals)

UROLOGY, NEPHROLOGY AND ANDROLOGY (159 journals)                     

Showing 1 - 159 of 159 Journals sorted alphabetically
Acta Urológica Portuguesa     Open Access   (Followers: 1)
Actas Urológicas Españolas     Full-text available via subscription   (Followers: 3)
Actas Urológicas Españolas (English Edition)     Full-text available via subscription   (Followers: 1)
Advances in Chronic Kidney Disease     Full-text available via subscription   (Followers: 11)
Advances in Urology     Open Access   (Followers: 13)
African Journal of Nephrology     Open Access  
African Journal of Urology     Open Access   (Followers: 7)
AJP Renal Physiology     Hybrid Journal   (Followers: 8)
Aktuelle Urologie     Hybrid Journal   (Followers: 4)
American Journal of Kidney Diseases     Hybrid Journal   (Followers: 42)
American Journal of Men's Health     Open Access   (Followers: 9)
American Journal of Nephrology     Full-text available via subscription   (Followers: 38)
Andrologia     Hybrid Journal   (Followers: 2)
Andrology     Hybrid Journal   (Followers: 4)
Andrology & Gynecology : Current Research     Hybrid Journal   (Followers: 4)
Andrology and Genital Surgery     Open Access   (Followers: 7)
Andrology-Open Access     Open Access  
Annales d'Urologie     Full-text available via subscription  
Arab Journal of Nephrology and Transplantation     Open Access   (Followers: 1)
Arab Journal of Urology     Open Access   (Followers: 7)
Archives of Clinical Nephrology     Open Access   (Followers: 2)
Archivio Italiano di Urologia e Andrologia     Open Access   (Followers: 1)
Archivos Españoles de Urología     Open Access  
Asian Journal of Andrology     Open Access   (Followers: 1)
Asian Journal of Urology     Open Access   (Followers: 3)
Bangladesh Journal of Urology     Open Access   (Followers: 5)
BANTAO Journal     Open Access  
Basic and Clinical Andrology     Open Access  
BJU International     Hybrid Journal   (Followers: 34)
BJUI Compass     Open Access   (Followers: 2)
BMC Nephrology     Open Access   (Followers: 11)
BMC Urology     Open Access   (Followers: 14)
Canadian Journal of Kidney Health and Disease     Open Access   (Followers: 8)
Canadian Urological Association Journal     Open Access   (Followers: 2)
Cancer Urology     Open Access   (Followers: 2)
Cardiorenal Medicine     Full-text available via subscription   (Followers: 1)
Case Reports in Nephrology     Open Access   (Followers: 5)
Case Reports in Nephrology and Dialysis     Open Access   (Followers: 9)
Case Reports in Urology     Open Access   (Followers: 12)
Clinical and Experimental Nephrology     Hybrid Journal   (Followers: 4)
Clinical Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 22)
Clinical Kidney Journal     Open Access   (Followers: 4)
Clinical Medicine Insights : Urology     Open Access   (Followers: 3)
Clinical Nephrology     Full-text available via subscription   (Followers: 8)
Clinical Nephrology and Urology Science     Open Access   (Followers: 6)
Clinical Queries: Nephrology     Hybrid Journal   (Followers: 1)
Cuadernos de Cirugía     Open Access   (Followers: 3)
Current Opinion in Nephrology & Hypertension     Hybrid Journal   (Followers: 10)
Current Opinion in Urology     Hybrid Journal   (Followers: 12)
Current Urology     Open Access   (Followers: 10)
Current Urology Reports     Hybrid Journal   (Followers: 5)
Der Nephrologe     Hybrid Journal  
Der Urologe     Hybrid Journal   (Followers: 1)
Diabetic Nephropathy     Open Access   (Followers: 1)
EMC - Urología     Full-text available via subscription  
Enfermería Nefrológica     Open Access   (Followers: 1)
European Urology     Full-text available via subscription   (Followers: 33)
European Urology Focus     Hybrid Journal   (Followers: 5)
European Urology Oncology     Hybrid Journal   (Followers: 1)
European Urology Open Science     Open Access   (Followers: 10)
Forum Nefrologiczne     Full-text available via subscription  
Geriatric Nephrology and Urology     Hybrid Journal   (Followers: 7)
Giornale di Clinica Nefrologica e Dialisi     Open Access  
Herald Urology     Open Access   (Followers: 2)
Hong Kong Journal of Nephrology     Open Access   (Followers: 3)
Human Andrology     Partially Free   (Followers: 2)
IJU Case Reports     Open Access  
Indian Journal of Nephrology     Open Access   (Followers: 2)
Indian Journal of Urology     Open Access   (Followers: 5)
International Brazilian Journal of Urology     Open Access   (Followers: 5)
International Journal of Nephrology     Open Access   (Followers: 2)
International Journal of Nephrology and Renovascular Disease     Open Access   (Followers: 2)
International Journal of Urology     Hybrid Journal   (Followers: 12)
International Urology and Nephrology     Hybrid Journal   (Followers: 7)
Jornal Brasileiro de Nefrologia     Open Access  
Journal für Urologie und Urogynäkologie/Österreich     Hybrid Journal  
Journal of Clinical Nephrology     Open Access   (Followers: 2)
Journal of Clinical Urology     Hybrid Journal   (Followers: 14)
Journal of Endoluminal Endourology     Open Access  
Journal of Endourology     Hybrid Journal   (Followers: 2)
Journal of Endourology Case Reports     Hybrid Journal  
Journal of Genital System & Disorders     Hybrid Journal   (Followers: 3)
Journal of Integrative Nephrology and Andrology     Open Access   (Followers: 2)
Journal of Kidney Cancer and VHL     Open Access  
Journal of Lower Genital Tract Disease     Hybrid Journal  
Journal of Nephrology     Hybrid Journal   (Followers: 4)
Journal of Nephrology Research     Open Access   (Followers: 3)
Journal of Pediatric Nephrology     Open Access   (Followers: 5)
Journal of Renal Care     Hybrid Journal   (Followers: 8)
Journal of Renal Nursing     Full-text available via subscription   (Followers: 12)
Journal of Renal Nutrition     Hybrid Journal   (Followers: 28)
Journal of Renal Nutrition and Metabolism     Open Access   (Followers: 1)
Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 31)
Journal of The Egyptian Society of Nephrology and Transplantation     Open Access  
Journal of Translational Neurosciences     Open Access  
Journal of Urology     Full-text available via subscription   (Followers: 46)
Journal of Urology & Nephrology     Open Access   (Followers: 2)
Kidney Disease and Transplantation     Open Access   (Followers: 4)
Kidney Diseases     Open Access   (Followers: 3)
Kidney International     Hybrid Journal   (Followers: 46)
Kidney International Reports     Open Access   (Followers: 3)
Kidney Medicine     Open Access  
Kidney Research Journal     Open Access   (Followers: 6)
Kidneys (Počki)     Open Access   (Followers: 1)
Nature Reviews Nephrology     Full-text available via subscription   (Followers: 22)
Nature Reviews Urology     Full-text available via subscription   (Followers: 13)
Nefrología (English Edition)     Open Access  
Nefrología (Madrid)     Open Access  
Nephro-Urology Monthly     Open Access   (Followers: 1)
Nephrology     Hybrid Journal   (Followers: 13)
Nephrology Dialysis Transplantation     Hybrid Journal   (Followers: 27)
Nephron     Hybrid Journal   (Followers: 4)
Nephron Clinical Practice     Full-text available via subscription   (Followers: 4)
Nephron Experimental Nephrology     Full-text available via subscription   (Followers: 4)
Nephron Extra     Open Access   (Followers: 1)
Nephron Physiology     Full-text available via subscription   (Followers: 4)
Neurourology and Urodynamics     Hybrid Journal   (Followers: 1)
OA Nephrology     Open Access   (Followers: 2)
Open Access Journal of Urology     Open Access   (Followers: 6)
Open Journal of Nephrology     Open Access   (Followers: 5)
Open Journal of Urology     Open Access   (Followers: 6)
Open Urology & Nephrology Journal     Open Access  
Pediatric Urology Case Reports     Open Access   (Followers: 7)
Portuguese Journal of Nephrology & Hypertension     Open Access   (Followers: 1)
Progrès en Urologie     Full-text available via subscription  
Progrès en Urologie - FMC     Full-text available via subscription  
Prostate Cancer and Prostatic Diseases     Hybrid Journal   (Followers: 6)
Renal Failure     Open Access   (Followers: 12)
Renal Replacement Therapy     Open Access   (Followers: 4)
Research and Reports in Urology     Open Access   (Followers: 4)
Revista de Nefrología, Diálisis y Trasplante     Open Access   (Followers: 1)
Revista Mexicana de Urología     Open Access   (Followers: 1)
Revista Urologia Colombiana     Open Access  
Saudi Journal of Kidney Diseases and Transplantation     Open Access   (Followers: 2)
Scandinavian Journal of Urology     Hybrid Journal   (Followers: 7)
Seminars in Nephrology     Hybrid Journal   (Followers: 11)
The Prostate     Hybrid Journal   (Followers: 8)
Therapeutic Advances in Urology     Open Access   (Followers: 4)
Trends in Urology & Men's Health     Partially Free   (Followers: 1)
Ukrainian Journal of Nephrology and Dialysis     Open Access   (Followers: 1)
Uro-News     Hybrid Journal   (Followers: 1)
Urolithiasis     Hybrid Journal   (Followers: 2)
Urologia Internationalis     Full-text available via subscription   (Followers: 2)
Urologia Journal     Hybrid Journal  
Urologic Clinics of North America     Full-text available via subscription   (Followers: 4)
Urologic Nursing     Full-text available via subscription   (Followers: 4)
Urologic Radiology     Hybrid Journal  
Urological Science     Open Access  
Urologicheskie Vedomosti     Open Access  
Urologie in der Praxis     Hybrid Journal  
Urologie Scan     Hybrid Journal  
Urology     Hybrid Journal   (Followers: 33)
Urology Annals     Open Access   (Followers: 4)
Urology Case Reports     Open Access   (Followers: 3)
Urology Practice     Full-text available via subscription   (Followers: 2)
Urology Times     Free   (Followers: 3)
Urology Video Journal     Open Access   (Followers: 1)
World Journal of Nephrology and Urology     Open Access   (Followers: 15)
World Journal of Urology     Hybrid Journal   (Followers: 11)

           

Similar Journals
Journal Cover
Clinical Journal of the American Society of Nephrology
Journal Prestige (SJR): 3.099
Citation Impact (citeScore): 5
Number of Followers: 22  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1555-9041 - ISSN (Online) 1555-905X
Published by American Society of Nephrology Homepage  [2 journals]
  • Patient Experiences with Home Dialysis
    • Authors: Myers J.
      Pages: 497 - 498
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.01570221
      Issue No: Vol. 16, No. 4 (2021)
       
  • Digital Solutions to Improve Medication Safety in CKD
    • Authors: Wagner, L.-A; Fink, J. C.
      Pages: 499 - 501
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.01680221
      Issue No: Vol. 16, No. 4 (2021)
       
  • A New View of Iron Management in Heart Failure: What Nephrologists Need to
           Know
    • Authors: Uppal, N. N; Fishbane, S.
      Pages: 502 - 504
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.01850221
      Issue No: Vol. 16, No. 4 (2021)
       
  • The Promise and Challenge of Aerobic Exercise in People Undergoing
           Long-Term Hemodialysis
    • Authors: Johansen K. L.
      Pages: 505 - 507
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.01960221
      Issue No: Vol. 16, No. 4 (2021)
       
  • Measuring Patient Experience with Home Dialysis in the United States
    • Authors: Brady, B. M; Kurella Tamura, M.
      Pages: 508 - 510
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.01990221
      Issue No: Vol. 16, No. 4 (2021)
       
  • Therapeutic Options to Improve Cardiovascular Outcomes with Long-Term
           Hemodialysis
    • Authors: Clark-Cutaia, M. N; Townsend, R. R.
      Pages: 511 - 513
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.02010221
      Issue No: Vol. 16, No. 4 (2021)
       
  • Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients: A
           Retrospective Single-Center Study
    • Authors: Karras, A; Livrozet, M, Lazareth, H, Benichou, N, Hulot, J.-S, Fayol, A, Chauvet, S, Jannot, A.-S, Penet, M.-A, Diehl, J.-L, Godier, A, Sanchez, O, Mirault, T, Thervet, E, Pallet, N, Pinot, Clerc, Arlet, Godier, Cholley
      Pages: 514 - 521
      Abstract: Background and objectivesKidney involvement is frequent among patients with coronavirus disease 2019 (COVID-19), and occurrence of AKI is associated with higher mortality in this population. The objective of this study was to describe occurrence and significance of proteinuria in this setting.Design, setting, participants & measurements We conducted a single-center retrospective study to describe the characteristic features of proteinuria measured within 48 hours following admission among patients with COVID-19 admitted in a tertiary care hospital in France, and to evaluate its association with initiation of dialysis, intensive care unit admission, and death.ResultsAmong 200 patients with available data, urine protein-creatinine ratio at admission was ≥1 g/g for 84 (42%), although kidney function was normal in most patients, with a median serum creatinine of 0.94 mg/dl (interquartile range, 0.75–1.21). Median urine albumin-creatinine ratio was 110 mg/g (interquartile range, 50–410), with a urine albumin-protein ratio
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.09130620
      Issue No: Vol. 16, No. 4 (2021)
       
  • Heart Failure Hospitalization Risk associated with Iron Status in Veterans
           with CKD
    • Authors: Cho, M. E; Hansen, J. L, Sauer, B. C, Cheung, A. K, Agarwal, A, Greene, T.
      Pages: 522 - 531
      Abstract: Background and objectivesCKD is an independent risk factor for heart failure. Iron dysmetabolism potentially contributes to heart failure, but this relationship has not been well characterized in CKD.Design, setting, participants, & measurementsWe performed a historical cohort study using data from the Veterans Affairs Corporate Data Warehouse to evaluate the relationship between iron status and heart failure hospitalization. We identified a CKD cohort with at least one set of iron indices between 2006 and 2015. The first available date of serum iron indices was identified as the study index date. The cohort was divided into four iron groups on the basis of the joint quartiles of serum transferrin saturation (shown in percent) and ferritin (shown in nanograms per milliliter): reference (16%–28%, 55–205 ng/ml), low iron (0.4%–16%, 0.9–55 ng/ml), high iron (28%–99.5%, 205–4941 ng/ml), and function iron deficiency (0.8%–16%, 109–2783 ng/ml). We compared 1-year heart failure hospitalization risk between the iron groups using matching weights derived from multinomial propensity score models and Poisson rate-based regression.ResultsA total of 78,551 veterans met the eligibility criteria. The covariates were well balanced among the iron groups after applying the propensity score weights (n=31,819). One-year adjusted relative rate for heart failure hospitalization in the iron deficiency groups were higher compared with the reference group (low iron: 1.29 [95% confidence interval, 1.19 to 1.41]; functional iron deficiency: 1.25 [95% confidence interval, 1.13 to 1.37]). The high-iron group was associated with lower 1-year relative rate of heart failure hospitalization (0.82; 95% confidence interval, 0.72 to 0.92). Furthermore, the association between iron deficiency and heart failure hospitalization risk remained consistent regardless of the diabetes status or heart failure history at baseline.ConclusionsIron deficiency, regardless of cause, was associated with higher heart failure hospitalization risk in CKD. Higher iron status was associated with lower heart failure hospitalization risks.
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.15360920
      Issue No: Vol. 16, No. 4 (2021)
       
  • Digital Applications Targeting Medication Safety in Ambulatory High-Risk
           CKD Patients: Randomized Controlled Clinical Trial
    • Authors: Ong, S. W; Jassal, S. V, Porter, E. C, Min, K. K, Uddin, A, Cafazzo, J. A, Rac, V. E, Tomlinson, G, Logan, A. G.
      Pages: 532 - 542
      Abstract: Background and objectivesPatients with CKD are at risk for adverse drug reactions, but effective community-based preventive programs remain elusive. In this study, we compared the effectiveness of two digital applications designed to improve outpatient medication safety.Design, setting, participants, & measurementsIn a 1-year randomized controlled trial, 182 outpatients with advanced CKD were randomly assigned to receive a smartphone preloaded with either eKidneyCare (n=89) or MyMedRec (n=93). The experimental intervention, eKidneyCare, includes a medication feature that prompted patients to review medications monthly and report changes, additions, or medication problems to clinicians for reconciliation and early intervention. The active comparator was MyMedRec, a commercially available, standalone application for storing medication and other health information that can be shared with patients' providers. The primary outcome was the rate of medication discrepancy, defined as differences between the patient’s reported history and the clinic’s medication record, at exit.ResultsAt exit, the eKidneyCare group had fewer total medication discrepancies compared with MyMedRec (median, 0.45; interquartile range, 0.33–0.63 versus 0.67; interquartile range, 0.40–1.00; P=0.001), and the change from baseline was 0.13±0.27 in eKidneyCare and 0.30±0.41 in MyMedRec (P=0.007). eKidneyCare use also reduced the severity of clinically relevant medication discrepancies in all categories, including those with the potential to cause serious harm (estimated rate ratio, 0.40; 95% confidence interval, 0.27 to 0.63). Usage data revealed that 72% of patients randomized to eKidneyCare completed one or more medication reviews per month, whereas only 30% of patients in the MyMedRec group (adjusted for dropouts) kept their medication profile on their phone.ConclusionsIn patients who are high risk and have CKD, eKidneyCare significantly reduced the rate and severity of medication discrepancies, the proximal cause of medication errors, compared with the active comparator.Clinical Trial registry name and registration number: www.ClinicalTrials.gov, NCT:02905474.
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.15020920
      Issue No: Vol. 16, No. 4 (2021)
       
  • Identification of Patients with CKD in Medical Databases: A Comparison of
           Different Algorithms
    • Authors: Vestergaard, S. V; Christiansen, C. F, Thomsen, R. W, Birn, H, Heide-Jorgensen, U.
      Pages: 543 - 551
      Abstract: Background and objectivesDespite CKD consensus definitions, epidemiologic studies use multiple different algorithms to identify CKD. We aimed to elucidate if this affects the patient characteristics and the estimated prevalence and prognosis of CKD by applying six different algorithms to identify CKD in population-based medical databases and compare the cohorts.Design, setting, participants, & measurementsPatients with CKD in Northern Denmark (2009–2016) were identified using six different algorithms: five were laboratory based defined by (1) one measured outpatient eGFR 60 ml/min per 1.73 m2 observed in-between (Kidney Disease Improving Global Outcomes, persistent, n=68,994), (4) two such findings ≥90 and
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.15691020
      Issue No: Vol. 16, No. 4 (2021)
       
  • Provider Perception of Frailty Is Associated with Dialysis Decision Making
           in Patients with Advanced CKD
    • Authors: Brar, R. S; Whitlock, R. H, Komenda, P. V. J, Rigatto, C, Prasad, B, Bohm, C, Tangri, N.
      Pages: 552 - 559
      Abstract: Background and objectivesFrailty is common in patients with CKD. Little is known about the prevalence of frailty and its effect on prognosis and decisions surrounding dialysis modalities in patients with advanced CKD (eGFR
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.12480720
      Issue No: Vol. 16, No. 4 (2021)
       
  • Effect of Aerobic Exercise on Dialysis-Related Symptoms in Individuals
           Undergoing Maintenance Hemodialysis: A Systematic Review and Meta-Analysis
           of Clinical Trials
    • Authors: Hargrove, N; El Tobgy, N, Zhou, O, Pinder, M, Plant, B, Askin, N, Bieber, L, Collister, D, Whitlock, R, Tangri, N, Bohm, C.
      Pages: 560 - 574
      Abstract: BackgroundHemodialysis is associated with a high symptom burden that impairs health-related quality of life and functional status. Effective symptom management is a priority for individuals receiving hemodialysis. Aerobic exercise may be an effective, nonpharmacologic treatment for specific hemodialysis-related symptoms. This systematic review investigated the effect of aerobic exercise on hemodialysis-related symptoms in adults with kidney failure undergoing maintenance hemodialysis.Design, setting, participants, & measurementsWe searched MEDLINE, PubMed, Cochrane CENTRAL, CINAHL, PsycINFO, SPORTDiscus, EMBASE, PEDro, and Scopus databases from 1960 or inception until April 15, 2020 for randomized controlled trials investigating the effect of aerobic exercise on hemodialysis-related symptoms, identified as prespecified primary or secondary outcomes, as compared with controls in adults on maintenance hemodialysis. We identified restless legs syndrome as the primary outcome.ResultsOf 3048 studies identified, 15 randomized controlled trials met the eligibility criteria. These studies investigated the effect of aerobic exercise on restless legs syndrome (two studies), sleep disturbance (four studies), anxiety (four studies), depression (nine studies), muscle cramping (one study), and fatigue (one study). Exercise interventions were intradialytic in ten studies and outside of hemodialysis in five studies. Heterogenous interventions and outcomes and moderate to high risk of bias precluded meta-analysis for most symptoms. Aerobic exercise demonstrated improvement in symptoms of restless legs syndrome, muscle cramping, and fatigue, as compared with nonexercise controls. Meta-analysis of depressive symptoms in studies using the Beck Depression Inventory demonstrated a greater reduction in Beck Depression Inventory score with exercise as compared with control (mean difference –7.57; 95% confidence interval, –8.25 to –6.89).ConclusionsOur review suggests that in adults on maintenance hemodialysis, aerobic exercise improves several hemodialysis-related symptoms, including restless legs syndrome, symptoms of depression, muscle cramping, and fatigue. However, the use of validated outcome measures with demonstrated reliability and responsiveness in more diverse hemodialysis populations is required to fully characterize the effect of this intervention.Clinical Trial registry name and registration number:PROSPERO #CRD42017056658
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.15080920
      Issue No: Vol. 16, No. 4 (2021)
       
  • Ramipril and Cardiovascular Outcomes in Patients on Maintenance
           Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial
    • Authors: Ruggenenti, P; Podesta, M. A, Trillini, M, Perna, A, Peracchi, T, Rubis, N, Villa, D, Martinetti, D, Cortinovis, M, Ondei, P, Condemi, C. G, Guastoni, C. M, Meterangelis, A, Granata, A, Mambelli, E, Pasquali, S, Genovesi, S, Pieruzzi, F, Bertoli, S. V, Del Rosso, G, Garozzo, M, Rigotti, A, Pozzi, C, David, S, Daidone, G, Mingardi, G, Mosconi, G, Galfre, A, Romei Longhena, G, Pacitti, A, Pani, A, Hidalgo Godoy, J, Anders, H.-J, Remuzzi, G, on behalf of the ARCADIA Study Organization, ARCADIA Study Organization, Remuzzi, Ondei, Condemi, Rota, Guastoni, Bellotti, Neri, Martina, Gidaro, Stasi, Meterangelis, Tamburello, Riva, Cortinovis, Granata, Salamone, Mancini, Persici, Sestigiani, Mambelli, Pasquali, Bovino, Stella, Genovesi, Fabbrini, Casiraghi, Bertoli, Tedoldi, Bigatti, Del Rosso, Malandra, Sassone, Garozzo, Battaglia, Rigotti, Cerretani, Bini, Pozzi, Corghi, David, Cantarelli, Blanco, Daidone, Ottaviano, Mingardi, Rota, Ledda, Mosconi, Zambianchi, Bolasco, Galfre, Murtas, Teatini, Longhena, Pacitti, Inguaggiato, Pani, Dessi, Scolari, Bove, Cozzolino, Pedone, Farina, Barbisoni, Scanziani, Santorelli, Spotti, Alibrandi, Conte, Stefani, Badalamenti, Valentino, Rubis, Calini, Diadei, Villa, Villa, Martinetti, Carminati, Giuliano, Perna, Peraro, Peracchi, Ruggenenti, Trillini, Podesta, Boccardo, Peracchi, Porrini, Sabadini, Peraro
      Pages: 575 - 587
      Abstract: Background and objectivesRenin-angiotensin system (RAS) inhibitors reduce cardiovascular morbidity and mortality in patients with CKD. We evaluated the cardioprotective effects of the angiotensin-converting enzyme inhibitor ramipril in patients on maintenance hemodialysis.Design, setting, participants, & measurementsIn this phase 3, prospective, randomized, open-label, blinded end point, parallel, multicenter trial, we recruited patients on maintenance hemodialysis with hypertension and/or left ventricular hypertrophy from 28 Italian centers. Between July 2009 and February 2014, 140 participants were randomized to ramipril (1.25–10 mg/d) and 129 participants were allocated to non-RAS inhibition therapy, both titrated up to the maximally tolerated dose to achieve predefined target BP values. The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the single components of the primary end point, new-onset or recurrence of atrial fibrillation, hospitalizations for symptomatic fluid overload, thrombosis or stenosis of the arteriovenous fistula, and changes in cardiac mass index. All outcomes were evaluated up to 42 months after randomization.ResultsAt comparable BP control, 23 participants on ramipril (16%) and 24 on non-RAS inhibitor therapy (19%) reached the primary composite end point (hazard ratio, 0.93; 95% confidence interval, 0.52 to 1.64; P=0.80). Ramipril reduced cardiac mass index at 1 year of follow-up (between-group difference in change from baseline: –16.3 g/m2; 95% confidence interval, –29.4 to –3.1), but did not significantly affect the other secondary outcomes. Hypotensive episodes were more frequent in participants allocated to ramipril than controls (41% versus 12%). Twenty participants on ramipril and nine controls developed cancer, including six gastrointestinal malignancies on ramipril (four were fatal), compared with none in controls.ConclusionsRamipril did not reduce the risk of major cardiovascular events in patients on maintenance hemodialysis.Clinical Trial registry name and registration number:ARCADIA, NCT00985322 and European Union Drug Regulating Authorities Clinical Trials Database number 2008–003529–17.
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.12940820
      Issue No: Vol. 16, No. 4 (2021)
       
  • Development and Content Validity of a Patient-Reported Experience Measure
           for Home Dialysis
    • Authors: Rivara, M. B; Edwards, T, Patrick, D, Anderson, L, Himmelfarb, J, Mehrotra, R.
      Pages: 588 - 598
      Abstract: Background and objectivesThe population of patients with kidney failure in the United States using home dialysis modalities is growing rapidly. Unlike for in-center hemodialysis, there is no patient-reported experience measure for assessment of patient experience of care for peritoneal dialysis or home hemodialysis. We sought to develop and establish content validity of a patient-reported experience measure for patients undergoing home dialysis using a mixed methods multiple stakeholder approach.Design, setting, participants, & measurementsWe conducted a structured literature review, followed by concept elicitation focus groups and interviews among 65 participants, including 21 patients on home dialysis, 33 home dialysis nurses, three patient care partners, and eight nephrologists. We generated a list of candidate items for possible measure inclusion and conducted a national prioritization exercise among 91 patients on home dialysis and 39 providers using a web-based platform. We drafted the Home Dialysis Care Experience instrument and conducted cognitive debriefing interviews to evaluate item interpretability, order, and structure. We iteratively refined the measure on the basis of interview findings.ResultsThe literature review and concept elicitation phases supported 15 domains of home dialysis care experience in six areas: communication and education of patients, concern and helpfulness of the care team, proficiency of the care team, patient-centered care, care coordination, and amenities and environment. Focus groups results showed that domains of highest importance for measure inclusion were patient education and communication, care coordination, and personalization of care. Prioritization exercise results confirmed focus group findings. Cognitive debriefing indicated that the final measure was easily understood and supported content validity.ConclusionsThe Home Dialysis Care Experience instrument is a 26-item patient-reported experience measure for use in peritoneal dialysis and home hemodialysis. The Home Dialysis Care Experience instrument represents the first rigorously developed and content-valid English-language instrument for assessment of patient-reported experience of care in home dialysis.
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.15570920
      Issue No: Vol. 16, No. 4 (2021)
       
  • Comparative Effects of Etelcalcetide and Maxacalcitol on Serum
           Calcification Propensity in Secondary Hyperparathyroidism: A Randomized
           Clinical Trial
    • Authors: Shoji, T; Nakatani, S, Kabata, D, Mori, K, Shintani, A, Yoshida, H, Takahashi, K, Ota, K, Fujii, H, Ueda, S, Nishi, S, Nakatani, T, Yoshiyama, M, Goto, K, Hamada, T, Imanishi, M, Ishimura, E, Kagitani, S, Kato, Y, Kumeda, Y, Maekawa, K, Matsumura, T, Nagayama, H, Obi, Y, Ohno, Y, Sai, Y, Sakurai, M, Sasaki, S, Shidara, K, Shoji, S, Tsujimoto, Y, Yamakawa, K, Yasuda, H, Yodoi, S, Inaba, M, Emoto, M.
      Pages: 599 - 612
      Abstract: Background and objectivesVitamin D receptor activators and calcimimetics (calcium-sensing receptor agonists) are two major options for medical treatment of secondary hyperparathyroidism. A higher serum calcification propensity (a shorter T50 value) is a novel surrogate marker of calcification stress and mortality in patients with CKD. We tested a hypothesis that a calcimimetic agent etelcalcetide is more effective in increasing T50 value than a vitamin D receptor activator maxacalcitol.Design, setting, participants, & measurementsA randomized, multicenter, open-label, blinded end point trial with active control was conducted in patients with secondary hyperparathyroidism undergoing hemodialysis in Japan. Patients were randomly assigned to receive intravenous etelcalcetide 5 mg thrice weekly (etelcalcetide group) or intravenous maxacalcitol 5 or 10 µg thrice weekly (maxacalcitol group). The primary, secondary, and tertiary outcomes were changes in T50 value, handgrip strength, and score of the Dementia Assessment Sheet for Community-Based Integrated Care System from baseline to 12 months, respectively.ResultsIn total, 425 patients from 23 dialysis centers were screened for eligibility, 326 patients were randomized (etelcalcetide, n=167; control, n=159), and 321 were included in the intention-to-treat analysis (median age, 66 years; 113 women [35%]). The median (interquartile range) of T50 value was changed from 116 minutes (interquartile range, 90–151) to 131 minutes (interquartile range, 102–176) in the maxacalcitol group, whereas it was changed from 123 minutes (interquartile range, 98–174) to 166 minutes (interquartile range, 127–218) in the etelcalcetide group. The increase in T50 value was significantly greater in the etelcalcetide group (difference in change, 20 minutes; 95% confidence interval, 7 to 34 minutes; P=0.004). No significant between-group difference was found in the change in handgrip strength or in the Dementia Assessment Sheet for Community-Based Integrated Care System score.ConclusionsEtelcalcetide was more effective in increasing T50 value than maxacalcitol among patients on hemodialysis with secondary hyperparathyroidism. There was no difference in handgrip strength or cognition between the two drugs.Clinical Trial registry name and registration number:VICTORY; UMIN000030636 and jRCTs051180156
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.16601020
      Issue No: Vol. 16, No. 4 (2021)
       
  • A Longitudinal, 3-Month Serologic Assessment of SARS-CoV-2 Infections in a
           Belgian Hemodialysis Facility
    • Authors: Labriola, L; Scohy, A, Seghers, F, Perlot, Q, De Greef, J, Desmet, C, Romain, C, Morelle, J, Yombi, J.-C, Kabamba, B, Rodriguez-Villalobos, H, Jadoul, M.
      Pages: 613 - 614
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.12490720
      Issue No: Vol. 16, No. 4 (2021)
       
  • Nephronophthisis in Young Adults Phenocopying Thrombotic Microangiopathy
           and Severe Nephrosclerosis
    • Authors: Doreille, A; Raymond, L, Lebre, A.-S, Linster, C, Saraeva Lamri, R, Karras, A, Khayat, R, Michel, P.-A, Buob, D, Luque, Y, Rafat, C, Mesnard, L.
      Pages: 615 - 617
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.11890720
      Issue No: Vol. 16, No. 4 (2021)
       
  • Expression of CD147 and Cyclophilin A in Kidneys of Patients with COVID-19
    • Authors: Su, H; Wan, C, Wang, Z.-D, Gao, Y, Li, Y.-C, Tang, F, Zhu, H.-Y, Yi, L.-X, Zhang, C.
      Pages: 618 - 619
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.09440620
      Issue No: Vol. 16, No. 4 (2021)
       
  • Inherited Tubulopathies of the Kidney: Insights from Genetics
    • Authors: Downie, M. L; Lopez Garcia, S. C, Kleta, R, Bockenhauer, D.
      Pages: 620 - 630
      Abstract: The kidney tubules provide homeostasis by maintaining the external milieu that is critical for proper cellular function. Without homeostasis, there would be no heartbeat, no muscle movement, no thought, sensation, or emotion. The task is achieved by an orchestra of proteins, directly or indirectly involved in the tubular transport of water and solutes. Inherited tubulopathies are characterized by impaired function of one or more of these specific transport molecules. The clinical consequences can range from isolated alterations in the concentration of specific solutes in blood or urine to serious and life-threatening disorders of homeostasis. In this review, we focus on genetic aspects of the tubulopathies and how genetic investigations and kidney physiology have crossfertilized each other and facilitated the identification of these disorders and their molecular basis. In turn, clinical investigations of genetically defined patients have shaped our understanding of kidney physiology.
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.14481119
      Issue No: Vol. 16, No. 4 (2021)
       
  • SGLT2 Inhibitors in Diabetic Kidney Disease
    • Authors: Zoungas, S; de Boer, I. H.
      Pages: 631 - 633
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.18881220
      Issue No: Vol. 16, No. 4 (2021)
       
  • Overview of Various Components of the Science of Patient Input: Advancing
           the Use of Patient-Reported, Real-World Evidence for Medical Device
           Evaluation of Innovative Products for the Treatment of Kidney Failure
           Using Strategically Coordinated Registry Networks
    • Authors: Sheldon M.
      Pages: 634 - 635
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.11760720
      Issue No: Vol. 16, No. 4 (2021)
       
  • Integrating Patient Perspectives into Medical Device Regulatory Decision
           Making to Advance Innovation in Kidney Disease
    • Authors: Tarver, M. E; Neuland, C.
      Pages: 636 - 638
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.11510720
      Issue No: Vol. 16, No. 4 (2021)
       
  • Incorporating Patient Preferences via Bayesian Decision Analysis
    • Authors: Chaudhuri, S. E; Lo, A. W.
      Pages: 639 - 641
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.12110720
      Issue No: Vol. 16, No. 4 (2021)
       
  • Using Patient Preference Information to Inform Regulatory Decision Making:
           An Opportunity to Spur Patient-Centered Innovation in Kidney Replacement
           Therapy Devices
    • Authors: Flythe, J. E; West, M.
      Pages: 642 - 644
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.11930720
      Issue No: Vol. 16, No. 4 (2021)
       
  • Legitimization and Incorporation of Patient Preferences: The Arrow that
           Hit the Achilles Heel of Status Quo Kidney Care
    • Authors: Conway, P. T; Knight, R.
      Pages: 645 - 647
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.11780720
      Issue No: Vol. 16, No. 4 (2021)
       
  • Risk Factors for CKD Progression: Overview of Findings from the CRIC Study
    • Authors: Hannan, M; Ansari, S, Meza, N, Anderson, A. H, Srivastava, A, Waikar, S, Charleston, J, Weir, M. R, Taliercio, J, Horwitz, E, Saunders, M. R, Wolfrum, K, Feldman, H. I, Lash, J. P, Ricardo, A. C, the CRIC Study Investigators, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators, Appel, Feldman, Go, He, Lash, Nelson, Rahman, Rao, Shah, Townsend, Unruh
      Pages: 648 - 659
      Abstract: The Chronic Renal Insufficiency Cohort (CRIC) Study is an ongoing, multicenter, longitudinal study of nearly 5500 adults with CKD in the United States. Over the past 10 years, the CRIC Study has made significant contributions to the understanding of factors associated with CKD progression. This review summarizes findings from longitudinal studies evaluating risk factors associated with CKD progression in the CRIC Study, grouped into the following six thematic categories: (1) sociodemographic and economic (sex, race/ethnicity, and nephrology care); (2) behavioral (healthy lifestyle, diet, and sleep); (3) genetic (apoL1, genome-wide association study, and renin-angiotensin-aldosterone system pathway genes); (4) cardiovascular (atrial fibrillation, hypertension, and vascular stiffness); (5) metabolic (fibroblast growth factor 23 and urinary oxalate); and (6) novel factors (AKI and biomarkers of kidney injury). Additionally, we highlight areas where future research is needed, and opportunities for interdisciplinary collaboration.
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.07830520
      Issue No: Vol. 16, No. 4 (2021)
       
  • Integrating Patient Priorities with Science by Community Engagement in the
           Kidney Precision Medicine Project
    • Authors: Tuttle, K. R; Knight, R, Appelbaum, P. S, Arora, T, Bansal, S, Bebiak, J, Brown, K, Campbell, C, Cooperman, L, Corona-Villalobos, C. P, Dighe, A, de Boer, I. H, Hall, D. E, Jefferson, N, Jolly, S, Kermani, A, Lee, S. C, Mehl, K, Murugan, R, Roberts, G. V, Rosas, S. E, Himmelfarb, J, Miller, R. T, for the Kidney Precision Medicine Project, Kidney Precision Medicine Project, Knight, Lecker, Stillman, Waikar, Colona, Kibblear, Mcmahon, Weins, Hacohen, Hoover, Aulisio, Cooperman, Herlitz, OToole, Poggio, Sedor, Appelbaum, Barasch, Balderes, Bomback, Dagati, Kiryluk, Mehl, Shang, Weng, Barisoni, Alexandrov, Ashkar, Barwinska, Dagher, Dunn, Eadon, Ferkowicz, Kelly, Sutton, Winfree, Menez, Parikh, Rosenberg, Villalobos, Slack, Rosas, Williams, Azeloglu, Hansen, He, Iyengar, Parikh, Rovin, Anderton, Pasa-Tolic, Velickovic, Oliver, Ardayfio, Bebiak, Brown, Campbell, Campbell, Hayashi, Jefferson, Koewler, Roberts, Saul, Shpigel, Stutzke, Wright, Miegs, Sealfon, Troyanskaya, Tuttle, Lake, Zhang, Joanes, Laszik, Balis, He, Hodgin, Kretzler, Mariani, Menon, Otto, Schaub, Steck, Elder, Hall, Kellum, Murugan, Palevsky, Randhawa, Rosengart, Sims-Lucas, Stefanick, Tublin, Alpers, de Boer, Fullerton, Himmelfarb, Mcclelland, Mooney, Shankland, Williams, Blank, Dighe, Carson, Dowd, Bansal, Sharma, Zhang, Kermani, Lee, Miller, Moe, Park, Sanchez, Torrealba, Toto, Vazquez, Wang, Gaut, Jain, Vijayan, Arora, Moledina, Ugochukwu, Wilson
      Pages: 660 - 668
      Abstract: The Kidney Precision Medicine Project (KPMP) is a multisite study designed to improve understanding of CKD attributed to diabetes or hypertension and AKI by performing protocol-driven kidney biopsies. Study participants and their kidney tissue samples undergo state-of-the-art deep phenotyping using advanced molecular, imaging, and data analytical methods. Few patients participate in research design or concepts for discovery science. A major goal of the KPMP is to include patients as equal partners to inform the research for clinically relevant benefit. The purpose of this report is to describe patient and community engagement and the value they bring to the KPMP. Patients with CKD and AKI and clinicians from the study sites are members of the Community Engagement Committee, with representation on other KPMP committees. They participate in KPMP deliberations to address scientific, clinical, logistic, analytic, ethical, and community engagement issues. The Community Engagement Committee guides KPMP research priorities from perspectives of patients and clinicians. Patients led development of essential study components, including the informed consent process, no-fault harm insurance coverage, the ethics statement, return of results plan, a "Patient Primer" for scientists and the public, and Community Advisory Boards. As members across other KPMP committees, the Community Engagement Committee assures that the science is developed and conducted in a manner relevant to study participants and the clinical community. Patients have guided the KPMP to produce research aligned with their priorities. The Community Engagement Committee partnership has set new benchmarks for patient leadership in precision medicine research.
      PubDate: 2021-04-07T11:00:26-07:00
      DOI: 10.2215/CJN.10270620
      Issue No: Vol. 16, No. 4 (2021)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.92.96.236
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-